2026 SPS Puerto Rico | Caplacizumab in the Immune-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Setting. A Real-World Evidence Review of CAPLA 1000+ and MAYARI Trial

2026 SPS Puerto Rico | Caplacizumab in the Immune-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Setting. A Real-World Evidence Review of CAPLA 1000+ and MAYARI Trial

0% Complete

Course Content

Caplacizumab in the Immune-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Setting. A Real-World Evidence Review of CAPLA 1000+ and MAYARI Trial

This material is non-CME, no credits are available, and a certificate will not be provided upon completion.

Course Details

Duration
0.00 hour
Released
Jun 22, 2026
Last Review
Jun 22, 2026
Expires
Jun 22, 2029

Target Audience

Pharmacists

Accreditation

NA

Related Courses

2026 SPS Puerto Rico | Specialty Pharmaceuticals: The Payer Perspective

2026 SPS Puerto Rico | Specialty Pharmaceuticals: The Payer Perspective

0.00 Credits
1 Chapter
Pharmacology
Free
2026 SPS Puerto Rico | Building Cell and Gene Therapy Program to Close Equity Gaps

2026 SPS Puerto Rico | Building Cell and Gene Therapy Program to Close Equity Gaps

0.00 Credits
1 Chapter
Pharmacology
Free
Explore More Courses